Eli Lilly and Company posted a surge in fourth-quarter revenues on Thursday, fuelled by strong demand for its blockbuster diabetes and weight-loss drugs.

The S&P 500 and Nasdaq ended higher with boosts from gains in Nvidia and Eli Lilly, while the Dow dipped slightly after a ...

Major Wall Street indexes saw slight gains on Thursday as strong earnings reports from companies like Eli Lilly, Tapestry, ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

Gift Nifty was trading around 23,710 level, a premium of nearly 20 points from the Nifty futures’ previous close, indicating ...

Please note: we will be discontinuing the Global Markets Report after 28 February. Australian shares are set to open lower, ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...